Inc Research Holdings, Inc. (INCR): James T. Ogle , director of Inc Research Holdings, Inc. sold 114,806 shares on Apr 18, 2016. The Insider selling transaction was reported by the company on Apr 19, 2016 to the Securities and Exchange Commission. The shares were sold at $50.00 per share for a total value of $5,740,300.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 14, 2016, D. Jamie Macdonald (Chief Executive Officer) sold 94,675 shares at $48.00 per share price.On Apr 4, 2016, Michael Gibertini (President Clinical Development) sold 9,000 shares at $40.78 per share price.Also, On Feb 5, 2016, Robert W Breckon (director) sold 3,882 shares at $39.76 per share price.On Feb 2, 2016, Gregory S Rush (Executive VP and CFO) sold 17,752 shares at $40.84 per share price.
INC Research Holdings Inc: On Monday, Apr 18, 2016 heightened volatility was witnessed in INC Research Holdings Inc which led to swings in the share price. The shares opened for trading at $49.53 and hit $57.11 on the upside , eventually ending the session at $49.68, with a gain of 0.75% or 0.37 points. The heightened volatility saw the trading volume jump to 62,21,533 shares. The 52-week high of the share price is $57.11 and the company has a market cap of $2,682 M . The 52-week low of the share price is at $29.03.
Company has been under the radar of several Street Analysts.INC Research Holdings Inc is Initiated by JP Morgan to Overweight and the brokerage firm has set the Price Target at $47. The Rating was issued on Mar 24, 2016.
In the past twelve weeks, the net percent change held by company insiders has changed by -72.8%.Institutional Investors own 78.59% of INC Research Holdings Inc shares.During last six month period, the net percent change held by insiders has seen a change of -72.8%.
INC Research Holdings Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company’s segment Clinical Development Services offers a variety of clinical development services including global studies clinical monitoring investigator recruitment patient recruitment data management and study reports. The Company’s segment Phase I Services focuses on clinical development services for Phase I trials that include scientific exploratory medicine first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The Company’s segment Global Consulting provides consulting services regarding clinical trial regulatory affairs regulatory consulting services quality assurance audits and pharmacovigilance consulting non-clinical consulting and medical writing consulting.